Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
Market Capitalization: 408.34 M
The data is delayed by 15 minutes.
AGEN is in the long-term down -62% below S&P in 6 years.
Description: Agenus Inc., a biopharmaceutical company, is developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines, and adjuvants. Its proprietary discovery engine Retrocyte Display is designed to generate therapeutic antibody drug candidates incorporating full-length IgG format human antibody libraries expressed in mammalian B-lineage cells. The company?s portfolio of checkpoint modulator programs is advancing in preclinical development. Its heat shock protein vaccines for cancer and infectious disease are in Phase II studies. The company?s QS-21 Stimulon adjuvant platform, which is partnered with GlaxoSmithKline and Janssen, includes various candidates in Phase III trials. In addition, it has 23 programs are in clinical development. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
|Shares Outstanding||86.88 M||EPS||-1.28||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||28.59%||Sales Growth - Q/Q||144.16%||P/E||-2.7|
|P/E To EPS Growth||P/S||40||P/BV||8.83||Price/Cash Per Share|
|Price/Free Cash Flow||-9.95||ROA||-51.88%||ROE||-131.58%||ROI|
|Current Ratio||4.06||Quick Ratio||4.05||Long Term Debt/Equity||Debt Ratio||0.45|
|Gross Margin||Operating Margin||-507.29%||Net Profit Margin||-596.23%||Dividend Payout Ratio|
|Cash From Financing Activities||36.1 M||Cash From Investing Activities||14.21 M||Cash From Operating Activities||3.3 M||Gross Profit|
|Net Profit||-40.41 M||Operating Profit||-33.2 M||Total Assets||117.32 M||Total Current Assets||85.15 M|
|Total Current Liabilities||21 M||Total Debt||11.5 M||Total Liabilities||71.07 M||Total Revenue||6.38 M|
|High 52 week||6.04||Low 52 week||1.59||Last close||2.66||Last change||0%|
|RSI||32.39||Average true range||0.12||Beta||1.14||Volume||925.23 K|
|Simple moving average 20 days||-2.22%||Simple moving average 50 days||-6.96%||Simple moving average 200 days||-17.66%|
|Performance Week||4.72%||Performance Month||-6.99%||Performance Quart||-21.53%||Performance Half||60.24%|
|Performance Year||-35.12%||Performance Year-to-date||11.76%||Volatility daily||2.12%||Volatility weekly||4.75%|
|Volatility monthly||9.73%||Volatility yearly||33.72%||Relative Volume||223.31%||Average Volume||1.27 M|
|New High||New Low|
2019-08-12 06:10:47 | Edited Transcript of AGEN earnings conference call or presentation 8-Aug-19 12:30pm GMT
2019-08-10 01:43:41 | Agenus Inc AGEN Q2 2019 Earnings Call Transcript
2019-08-09 11:09:03 | Agenus AGEN Q2 Earnings Miss Estimates, Revenues Beat
2019-08-08 09:35:01 | Agenus AGEN Reports Q2 Loss, Tops Revenue Estimates
2019-08-08 07:30:00 | Agenus Reports Second Quarter 2019 Financial Results and Provides Corporate Update
2019-08-08 07:30:00 | Agenus Milestone Triggers $7.5M Payment
2019-07-26 11:04:29 | Is Agenus NASDAQ:AGEN Using Too Much Debt?
2019-07-18 14:00:00 | Agenus Appoints Don Vidic as Vice President and Head of Commercial
2019-07-08 09:00:01 | Agenus AGEN Upgraded to Buy: What Does It Mean for the Stock?
2019-06-26 06:24:10 | Gilead Inks Deal With Carna Biosciences for Immuno-Oncology
2019-06-20 09:36:20 | How Many Agenus Inc. NASDAQ:AGEN Shares Do Institutions Own?
2019-06-20 06:33:10 | Gilead GILD Teams Up With Nurix for Cancer and Other Drugs
2019-06-13 15:48:00 | Agenus to Host Annual Meeting of Stockholders
2019-06-08 09:31:01 | Why Is Agenus AGEN Down 6.3% Since Last Earnings Report?
2019-05-24 10:53:02 | Agenus' AGEN Pipeline Progression on Track Amid Competition
2019-05-10 14:54:06 | Agenus AGEN Q1 Earnings Beat Estimates, Revenues Miss
2019-05-10 07:24:11 | Agenus Inc AGEN Q1 2019 Earnings Call Transcript
2019-05-09 18:03:27 | Edited Transcript of AGEN earnings conference call or presentation 9-May-19 12:30pm GMT
2019-05-09 09:05:01 | Agenus AGEN Surpasses Q1 Earnings Estimates
2019-05-09 07:57:18 | Agenus: 1Q Earnings Snapshot
2019-05-09 07:30:00 | Agenus Reports First Quarter 2019 Financial Results and Provides Corporate Update
2019-05-09 06:30:00 | Agenus, Inc. to Host Earnings Call
2019-04-13 09:30:01 | Why Is Agenus AGEN Down 13% Since Last Earnings Report?
2019-04-08 17:25:09 | Gilead Files sNDA for Label Expansion of HIV Therapy Descovy
2019-04-02 08:30:00 | Agenus Begins Dosing with Next-Gen Anti-CTLA-4 Antibody
2019-03-21 09:00:00 | Agenus Announces Clinical Appointments
2019-03-20 09:15:00 | 3 Top Growth Stocks to Buy Right Now
2019-03-14 13:34:34 | Edited Transcript of AGEN earnings conference call or presentation 14-Mar-19 12:30pm GMT
2019-03-14 11:13:03 | Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up
2019-03-14 10:55:13 | Agenus Inc AGEN Q4 2018 Earnings Conference Call Transcript
2019-03-14 09:30:01 | Agenus AGEN Reports Q4 Loss, Lags Revenue Estimates
2019-03-14 08:35:18 | Agenus: 4Q Earnings Snapshot
2019-03-13 08:30:00 | Agenus Milestone Triggers $7.5M Payment from Gilead
2019-03-08 15:46:08 | Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy
2019-03-07 13:50:06 | Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy
2019-03-03 19:09:00 | The 3 Oldest Members of Biotech's Billion-Burned Club
2019-02-20 08:30:00 | Analysis: Positioning to Benefit within Micron Technology, Caterpillar, Agenus, Fossil Group, Marathon Petroleum, and Geo Group — Research Highlights Growth, Revenue, and Consolidated Results
2019-02-19 08:30:00 | Agenus Launches First Asset-Backed Digital-Security Offering in Healthcare
2019-02-08 10:25:00 | Why Agenus Inc. Stock Took Flight in January
2019-02-05 08:43:01 | Gilead GILD Q4 Earnings Miss Estimates, Revenues Beat
2019-01-31 19:18:12 | Will Gilead GILD Q4 Earnings Disappoint on Weak HCV Sales?
2019-01-29 08:00:00 | Agenus to Launch the First Asset-Backed Digital Security Offering in Healthcare
2019-01-24 08:30:00 | Agenus Closes $150 Million Immuno-Oncology Transaction with Gilead